Related Experiment Video
Updated: Nov 25, 2025

Digestion of Whole Mouse Eyes for Multi-Parameter Flow Cytometric Analysis of Mononuclear Phagocytes
Published on: June 17, 2020
Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions
Benjamin J Kim1, Dimitrios C Mastellos2, Yafeng Li1
1Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Insights
Age-related macular degeneration (AMD) treatments are lacking for geographic atrophy. Targeting complement system proteins C3 and C5 shows promise for new AMD therapies, offering different inhibition strategies.
Area of Science:
- Ophthalmology
- Immunology
- Biochemistry
Background:
- Age-related macular degeneration (AMD) causes legal blindness, with geographic atrophy being a key unmet therapeutic need.
- Complement cascade dysregulation is implicated in AMD pathogenesis.
- C3 and C5 are central complement components and emerging therapeutic targets for AMD.
Purpose of the Study:
- To provide a detailed review of C3 and C5 biology in AMD.
- To critically assess therapeutic strategies targeting C3 and C5.
- To explore connections between complement, inflammasome, and microglia/macrophage activity in AMD.
Main Methods:
- Literature review and critical analysis of existing research on C3, C5, and AMD.
- Discussion of biochemical and structural properties of C3 and C5.
- Examination of therapeutic approaches targeting C3 and C5.
Main Results:
- C3 and C5 play critical roles in AMD pathophysiology.
- Therapeutics targeting C3 offer broad complement inhibition, while C5 inhibitors provide specificity.
- Understanding C3/C5 interactions with inflammasomes and immune cells is crucial.
Conclusions:
- Targeting C3 and C5 represents a promising avenue for AMD geographic atrophy treatment.
- The choice between broad C3 inhibition and specific C5 inhibition requires further investigation.
- Future research should focus on clarifying C3/C5 biology and its interplay with other inflammatory pathways in AMD.
Abstract:
Age-related macular degeneration (AMD) remains a major cause of legal blindness, and treatment for the geographic atrophy form of AMD is a significant unmet need. Dysregulation of the complement cascade is thought to be instrumental for AMD pathophysiology. In particular, C3 and C5 are pivotal components of the complement cascade and have become leading therapeutic targets for AMD. In this article, we discuss C3 and C5 in detail, including their roles in AMD, biochemical and structural aspects, locations of expression, and the functions of C3 and C5 fragments. Further, the article critically reviews developing therapeutics aimed at C3 and C5, underscoring the potential effects of broad inhibition of complement at the level of C3 versus more specific inhibition at C5. The relationships of complement biology to the inflammasome and microglia/macrophage activity are highlighted. Concepts of C3 and C5 biology will be emphasized, while we point out questions that need to be settled and directions for future investigations.
Related Concept Videos
Complement System
Anatomy of the Eyeball
The Retina
Photoreceptors and Visual Pathways

